Home » FDA Lifts Clinical Hold on Lpath’s iSONEP

FDA Lifts Clinical Hold on Lpath’s iSONEP

August 27, 2012

Lpath reported that the FDA has lifted the clinical hold on iSONEP, Lpath’s anti-S1P monoclonal antibody that is being developed as a potential treatment for wet AMD and possibly other ocular disorders.
Yahoo! Finance

19Jan
Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management
21Jan
Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits
26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
27Jan
FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations
09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Lifts Clinical Hold on Lpath’s iSONEP

Upcoming Events

Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements